Breakthrough for Superbug Resistance with MCR Inhibitors
Combination of Polymyxin Antibiotic and Mobile Colistin Resistant Protein Inhibitor for Treating Superbug
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This technology combines polymyxin antibiotics with inhibitors of mobile colistin-resistant (MCR) proteins to effectively combat Gram-negative bacterial infections, including those resistant to colistin. The gold or silver-based inhibitors enhance antibiotic penetration into bacteria, restoring potency against superbugs. The combination therapy has demonstrated efficacy in vivo and offers a broad spectrum of action against carbapenem- and colistin-resistant strains. Applications include treating severe infections caused by MCR-carrying bacteria, leveraging drug repurposing for faster deployment. A patent application (PCT/WO/2021/036923) has been submitted to secure intellectual property rights.
IP Type or Form Factor: Patent Pending; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Pharmaceutical Engineering; Public Health & Universal Healthcare
